GlassScriptPhysician profile
Milan C Patel
NPI 1659340743
$4,779.48
in general payments reported to CMS, 2019-2025
29 companies · $769 in 2025
The $769 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,337 · 2020: $442 · 2021: $194 · 2022: $177 · 2023: $334 · 2024: $527 · 2025: $769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,383 · Education: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,382.81 |
| Education | $246.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,048.65 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $608.36 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Sk Life Science, INC. | $607.28 | 2022-2025 | |
| Eisai INC. | $578.77 | 2019-2025 | |
| Allergan, INC. | $350.91 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $249.30 | 2019-2020 | |
| Ucb, INC. | $154.25 | 2019-2020 | |
| Catalyst Pharmaceuticals, INC. | $132.27 | 2023-2025 | Fycompa |
| Abbvie INC. | $119.26 | 2023-2025 | |
| Amgen INC. | $113.99 | 2019-2020 | |
| Portola Pharmaceuticals, LLC | $110.90 | 2019 | |
| Janssen Biotech, INC. | $108.00 | 2024 | Simponi Aria |
| Acadia Pharmaceuticals INC | $94.54 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $84.29 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $69.18 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $51.98 | 2023 | Aptiom |
| Lilly USA, LLC | $37.66 | 2019 | |
| Octapharma USA, INC. | $34.80 | 2024 | Panzyga |
| Vertical Pharmaceuticals, LLC | $34.09 | 2019 | |
| Amneal Pharmaceuticals LLC | $32.95 | 2019 | |
| Abbott Laboratories | $29.10 | 2019 | |
| Lundbeck LLC | $25.85 | 2024 | Vyepti |
| Biogen, INC. | $18.30 | 2019 | |
| Genzyme Corporation | $17.65 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.68 | 2021 | |
| Pfizer INC. | $15.20 | 2025 | |
| Kyowa Kirin, INC. | $13.01 | 2019 | |
| Boston Scientific Corporation | $12.33 | 2022 | |
| Adamas Pharmaceuticals, INC. | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milan Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.